Foong, Y. C. Et Al. 2024. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60. Journal of Neurology, Neurosurgery and Psychiatry , vol.95, no.8 , 767-774.

Foong, Y. C., Merlo, D., Gresle, M., Buzzard, K., Zhong, M., Yeh, W. Z., ... Jokubaitis, V.(2024). Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60. Journal of Neurology, Neurosurgery and Psychiatry , vol.95, no.8, 767-774.

Foong, Yi Et Al. "Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60," Journal of Neurology, Neurosurgery and Psychiatry , vol.95, no.8, 767-774, 2024

Foong, Yi C. Et Al. "Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60." Journal of Neurology, Neurosurgery and Psychiatry , vol.95, no.8, pp.767-774, 2024

Foong, Y. C. Et Al. (2024) . "Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60." Journal of Neurology, Neurosurgery and Psychiatry , vol.95, no.8, pp.767-774.

@article{article, author={Yi Chao Foong Et Al. }, title={Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60}, journal={Journal of Neurology, Neurosurgery and Psychiatry}, year=2024, pages={767-774} }